Table 1.
Baseline characteristics (N=23).
| Characteristic | N (%) |
|---|---|
| Age, years | |
| Mean | 62 |
| Range | 43–77 |
| Race | |
| White | 17 (74%) |
| Black or African American | 2 (9%) |
| Asian | 2 (9%) |
| Unknown | 2 (9%) |
| No. of prior platinum-based therapies | |
| 0 | 8 (35%) |
| 1 | 14 (61%) |
| 2 | 1 (4%) |
| ECOG performance status | |
| 0 | 18 (78%) |
| 1 | 5 (22%) |
| Cancer type | |
| Endometrial cancer | 18 (78%) |
| Endometrioid grade 1 | 1 (4%) |
| Endometrioid grade 2 | 2 (9%) |
| Endometrioid grade 3 | 3 (13%) |
| Serous/high grade | 6 (26%) |
| Carcinosarcoma | 6 (26%) |
| Ovarian cancera | 5 (22%) |
| Serous | 5 (22%) |
| Stage at diagnosis | |
| Endometrial cancer | 18 (78%) |
| I | 8 (35%) |
| II | 0 |
| III | 2 (9%) |
| IV | 8 (35%) |
| Ovarian cancer | 5 (22%) |
| III | 4 (17%) |
| IV | 1 (4%) |
ECOG=Eastern Cooperative Oncology Group; No.=number.
a
All patients with ovarian cancer had received a platinum-based therapy ≥6 months prior.